Search results for "Hepatitis C virus"


 
Results 1 - 10 of about 35 for "Hepatitis C virus".

Review: In chronic hepatitis C virus infection, oral direct-acting antivirals have high sustained virologic response | ACP Gastroenterology Monthly

A commentary in ACP Journal Club noted that while screening and treating all patients with chronic hepatitis C virus (HCV) would be cost-effective and probably cost-saving, some payers are still resistant.

ACP Gastroenterology Monthly

ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.

Spotlight on direct-acting antivirals | ACP Gastroenterology Monthly

Studies of contemporary populations with hepatitis C virus infection demonstrated that treatment with direct-acting antiviral therapies was linked to improvement in several long-term clinical outcomes.

Reformulation of extended-release oxycodone may have triggered increase in hepatitis C rates | ACP Gastroenterology Monthly

Hepatitis C virus infections increased three times faster in states with above-median rates of initial misuse of extended-release oxycodone (OxyContin) than in states with below-median rates, and the increase began immediately after a reformulation

Transplant of HCV-infected kidneys to HCV-negative recipients yields good outcomes at 12 months | ACP Gastroenterology Monthly

The study authors concluded that their results should encourage efforts to increase use of hepatitis C virus (HCV)-infected kidneys and called for larger confirmatory trials.

August 25, 2017 | ACP Gastroenterology Monthly

ACP Gastroenterology Monthly delivers a monthly summary of news in gastroenterology and hepatology, including the latest research, clinical guidelines, and FDA drug actions.

HCV-infected kidney transplants appear cost-effective in recipients with HCV | ACP Gastroenterology Monthly

Transplanting a hepatitis C virus (HCV)-infected kidney and then administering HCV treatment was more effective and cost less than transplanting an HCV-uninfected kidney after HCV treatment in HCV-infected patients, mainly because the waiting list

High HCV cure rate seen with FDA-approved direct-acting antiviral regimens | ACP Gastroenterology Monthly

Six of the direct-acting antiviral (DAA) regimens yielded sustained virologic response rates above 95% in patients who had hepatitis C virus (HCV) genotype 1 without cirrhosis, including those with HIV co-infection.

HCV treatment was successful among patients who used injection drugs | ACP Gastroenterology Monthly

The open-label, single-arm, industry-funded phase 4 trial included patients who had used injection drugs within six months and had chronic hepatitis C virus (HCV), recruited at 19 sites in seven countries.

HCV treatment appeared successful for patients who hadn't responded to previous direct-acting antivirals, industry-funded study finds | ACP Gastroenterology Monthly

The study included two phase 3 trials: POLARIS-1, in which patients with chronic hepatitis C virus (HCV) had previously taken a regimen containing an NS5A inhibitor, and POLARIS-4, in which patients had previously received a direct-acting antiviral

Result Page: Prev   1   2   3   4   Next